China-based Lynk Pharmaceuticals has officially submitted a listing application to the Hong Kong Stock Exchange (HKEX), with CITIC Securities and CCB International acting as joint sponsors. The company, which commenced operations in 2018, is a clinical-stage biopharmaceutical firm focused on discovering and developing novel, differentiated small-molecule inhibitors for autoimmune and inflammatory diseases. Its clinical-stage pipeline primarily targets the JAK-STAT signalling pathway and features core assets such as LNK01001, a potentially best-in-class second-generation JAK1 inhibitor, and LNK01004, a potentially first-in-class third-generation soft pan-JAK inhibitor.

A key component of Lynk's strategy is its proprietary IsoNova protein degradation platform, which is designed to enhance selectivity and safety by eliminating inactive isomers. This platform has generated several preclinical candidates, including degraders targeting STAT6, VAV1, IRAK4 and NEK7, with potential applications beyond immunology in oncology and neurodegenerative diseases. Financially, the company reported net losses of RMB 259.6 million, RMB 312.3 million and RMB 145.4 million for 2023, 2024 and the nine months ended 30 September 2025, respectively, driven largely by R&D expenditures.

According to PharmCube's MedAlpha® database, the company has been previously backed by investors including Lilly Asia Ventures and Legend Capital. Click here to request a free trial for MedAlpha®.